D60.8
Other acquired pure red cell aplasias
Clinical Classification Guidelines
Medical Intelligence & Overview
Other acquired pure red cell aplasias refer to a group of rare blood disorders characterized by the body's inability to produce red blood cells. This condition belongs to a broader category of bone marrow failure syndromes that specifically impair the development of erythroid cells, leading to anemia. Usually acquired rather than inherited, this disorder affects individuals across various age groups and can vary in severity.
Causes & Symptoms
Clinical Causes: Autoimmune reactions where the body's immune system mistakenly attacks red blood cell precursors in the bone marrow. Exposure to certain drugs, toxins, or chemicals that suppress red blood cell production. Viral infections such as parvovirus B19 can temporarily disrupt red blood cell production. Other underlying medical conditions that may interfere with bone marrow function. Idiopathic cases where no specific cause can be identified.
Key Symptoms: Persistent fatigue and weakness due to anemia. Pale skin or pallor. Shortness of breath especially during exertion. Rapid or irregular heartbeat. Dizziness or lightheadedness. In severe cases, symptoms of heart strain or chest pain. Possible pallor of the nail beds or mucous membranes.
Diagnostic & Treatment
Diagnosis Path: The diagnosis of other acquired pure red cell aplasias involves a combination of medical history, physical examination, and laboratory tests. Blood tests typically reveal anemia characterized by low red blood cell counts, with normal white blood cell and platelet levels. A bone marrow biopsy is essential to assess marrow activity, often showing a marked reduction or absence of erythroid precursors while other marrow elements remain normal. Additional tests may include checking for related infections, autoimmune markers, and drug or toxin exposure history to identify potential causes.
Treatment Protocols: Management strategies focus on treating the underlying cause if identified and supporting red blood cell production. Approaches may include corticosteroids or immunosuppressive therapy to curb autoimmune activity, blood transfusions for severe anemia relief, and discontinuing any causative drugs or toxins. In some cases, growth factors such as erythropoietin may be used to stimulate red blood cell production. For persistent or severe cases, bone marrow transplantation might be considered. Regular monitoring and supportive care are crucial to address ongoing symptoms and prevent complications.
Clinical Advice & FAQs
Billing Guidance
Is D60.8 a billable ICD-10 code?
Yes, D60.8 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D60.8?
Clinical documentation must specify the nature of Other acquired pure red cell aplasias and any associated comorbidities for accurate reporting.
Cite this Clinical Reference